Somerset Therapeutics LLC

Prem Sagar Akasapu

Veerappan Subramanian

Ilango Subramanian

Rahul Kalhapure

Mandar V Shah

Shambhavi Borde

The invention described here provides ready-to-use (RTU) pharmaceutical compositions in single unit dose packaging, such compositions including ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The compositions provided by the invention are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use. In certain aspects, the invention comprises methods of using such compositions in the treatment of diseases, conditions, or symptoms related to vitamin C deficiency, such as, in specific embodiments, scurvy.

Ready-to-use ascorbic acid compound compositions

The invention described here provides methods of efficiently treating vitamin C deficiency-related diseases and other conditions comprising the administration of pharmaceutical compositions comprising ascorbic acid compound(s), such as sodium ascorbate, and one or more pharmaceutically acceptable excipients (e.g., a carrier and optionally other agents, such as a tonicity agent, a chelator, or both). The methods comprise administration of such compositions in ready-to-use (RTU) form, provided in single unit dose packaging, wherein the compositions are stable when stored at 20° C. to 25° C.±2° C. for at least about 3 months. Compositions provided by the invention comprise an osmolality of between about 270 mOsm/kg to about 340 mOsm/kg and do not require dilution or further manipulation prior to use.

Methods of efficiently treating vitamin C deficiency-related diseases and other conditions

The present invention provides an emulsion composition comprising aprepitant for treatment of emesis. Particularly, the invention is a ready-to-use emulsion compositions comprising aprepitant and medium chain triglycerides for administration by intravenous infusion, wherein the emulsion composition is also free of ethanol. Further, the invention also provides processes of preparing such compositions and their use for the prevention and control of acute and delayed chemotherapy-induced nausea and vomiting, and/or for prevention of postoperative nausea and vomiting.

Aprepitant ready-to-use injection emulsion compositions

The present invention relates to a process for preparation of a water-insoluble steroid composition by moist heat sterilization. The invention particularly relates to a process for preparation of a water-insoluble steroid composition comprising moist heat sterilization or autoclaving of an aqueous slurry of methylprednisolone acetate in the presence of a specified quantity of polysorbate. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Preparation of microparticulate methylprednisolone acetate suspension

The present invention relates to liquid formulations of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulations are devoid of tromethamine. In particular, the invention provides a stable ready-to-use liquid formulation of levothyroxine or a pharmaceutically acceptable salt thereof intended for parenteral administration, wherein the formulation is devoid of tromethamine. The formulations prepared by using the current invention exhibit good physical and chemical stability.

Liquid ready-to-use formulation of levothyroxine

The present invention relates to a process for preparation of an insoluble corticosteroid and a soluble corticosteroid composition by moist heat sterilization and homogenization. In particular, the invention relates to a process for the preparation of a sterilized suspension of betamethasone acetate and betamethasone sodium phosphate, wherein the process comprises sterilizing a slurry of the betamethasone acetate by moist heat sterilization or autoclaving in about 30% to about 70% of water to a temperature of about 115&#xb0; C. to about 128&#xb0; C. for about 15 minutes to about 60 minutes under nitrogen atmosphere. The suspensions prepared by using the current invention exhibited good physical and chemical stability. Compositions related thereto are also disclosed.

Growing community of inventors

Somerset, NJ, United States of America

Prem Sagar Akasapu